Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze...

Full description

Bibliographic Details
Main Authors: Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-25769-z
id doaj-d25f24d7eb06482f96ec27595b0111bc
record_format Article
spelling doaj-d25f24d7eb06482f96ec27595b0111bc2021-09-26T11:44:28ZengNature Publishing GroupNature Communications2041-17232021-09-0112111310.1038/s41467-021-25769-zMolecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E. Keenan0Jennifer L. Guerriero1Romualdo Barroso-Sousa2Tianyu Li3Tess O’Meara4Anita Giobbie-Hurder5Nabihah Tayob6Jiani Hu7Mariano Severgnini8Judith Agudo9Ines Vaz-Luis10Leilani Anderson11Victoria Attaya12Jihye Park13Jake Conway14Meng Xiao He15Brendan Reardon16Erin Shannon17Gerburg Wulf18Laura M. Spring19Rinath Jeselsohn20Ian Krop21Nancy U. Lin22Ann Partridge23Eric P. Winer24Elizabeth A. Mittendorf25David Liu26Eliezer M. Van Allen27Sara M. Tolaney28Department of Medical Oncology, Dana-Farber Cancer InstituteBreast Tumor Immunology Laboratory, Department of Cancer Biology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, BostonDepartment of Medical Oncology, Dana-Farber Cancer InstituteDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, BostonDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, BostonDivision of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, BostonCenter for Immuno-Oncology, Dana-Farber Cancer InstituteDepartment of Cancer Immunology and Virology, Dana-Farber Cancer InstituteMedical Oncology Department, INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Institut Gustave RoussyDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBroad Institute of Massachusetts Institute of Technology and HarvardHematology/Oncology, Beth Israel Deaconess Medical CenterBreast Cancer, Cancer Center, Massachusetts General HospitalDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteBreast Oncology Program, Dana-Farber/Brigham and Women’s Cancer CenterDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteDepartment of Medical Oncology, Dana-Farber Cancer InstituteA randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze molecular correlateshttps://doi.org/10.1038/s41467-021-25769-z
collection DOAJ
language English
format Article
sources DOAJ
author Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
spellingShingle Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
Nature Communications
author_facet Tanya E. Keenan
Jennifer L. Guerriero
Romualdo Barroso-Sousa
Tianyu Li
Tess O’Meara
Anita Giobbie-Hurder
Nabihah Tayob
Jiani Hu
Mariano Severgnini
Judith Agudo
Ines Vaz-Luis
Leilani Anderson
Victoria Attaya
Jihye Park
Jake Conway
Meng Xiao He
Brendan Reardon
Erin Shannon
Gerburg Wulf
Laura M. Spring
Rinath Jeselsohn
Ian Krop
Nancy U. Lin
Ann Partridge
Eric P. Winer
Elizabeth A. Mittendorf
David Liu
Eliezer M. Van Allen
Sara M. Tolaney
author_sort Tanya E. Keenan
title Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_short Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_full Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_fullStr Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_full_unstemmed Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
title_sort molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2021-09-01
description A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze molecular correlates
url https://doi.org/10.1038/s41467-021-25769-z
work_keys_str_mv AT tanyaekeenan molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jenniferlguerriero molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT romualdobarrososousa molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT tianyuli molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT tessomeara molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT anitagiobbiehurder molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT nabihahtayob molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jianihu molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT marianosevergnini molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT judithagudo molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT inesvazluis molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT leilanianderson molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT victoriaattaya molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jihyepark molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT jakeconway molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT mengxiaohe molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT brendanreardon molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT erinshannon molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT gerburgwulf molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT lauramspring molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT rinathjeselsohn molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT iankrop molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT nancyulin molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT annpartridge molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT ericpwiner molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT elizabethamittendorf molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT davidliu molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT eliezermvanallen molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
AT saramtolaney molecularcorrelatesofresponsetoeribulinandpembrolizumabinhormonereceptorpositivemetastaticbreastcancer
_version_ 1716867810665168896

Similar Items